Risk estimation for the next generation of prevention programmes for cervical cancer.
作者信息
Katki Hormuzd A, Wacholder Sholom, Solomon Diane, Castle Philip E, Schiffman Mark
机构信息
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20852, USA.
出版信息
Lancet Oncol. 2009 Nov;10(11):1022-3. doi: 10.1016/S1470-2045(09)70253-0. Epub 2009 Sep 18.
Abstract
摘要
相似文献
1
Risk estimation for the next generation of prevention programmes for cervical cancer.下一代宫颈癌预防计划的风险评估。
Lancet Oncol. 2009 Nov;10(11):1022-3. doi: 10.1016/S1470-2045(09)70253-0. Epub 2009 Sep 18.
2
A participatory assessment to identify strategies for improved cervical cancer prevention and treatment in Bolivia.一项旨在确定改善玻利维亚宫颈癌预防与治疗策略的参与式评估。
Rev Panam Salud Publica. 2005 Jul;18(1):53-63. doi: 10.1590/s1020-49892005000600012.
3
Development of a public health research program for ovarian cancer.卵巢癌公共卫生研究项目的开展
J Womens Health (Larchmt). 2006 May;15(4):339-45. doi: 10.1089/jwh.2006.15.339.
4
5
Cervical screening: alternative services.宫颈癌筛查：替代服务。
N Z Nurs J. 1987 Oct;80(10):25-6.
6
[Summary of the screening program for cervical cancer prevention in Poland for the first six months of 2007].[2007年上半年波兰宫颈癌预防筛查项目总结]
Ginekol Pol. 2007 Oct;78(10):821-2.
7
Prison: Pipeline to Women's Preventative Health.监狱：通往女性预防性健康的渠道。
R I Med J (2013). 2018 Oct 1;101(8):23-26.
8
Preventing cervical cancer in low-resource settings: building a case for the possible.在资源匮乏地区预防宫颈癌：为可能性提供依据
Int J Gynaecol Obstet. 2005 May;89 Suppl 2:S1-3. doi: 10.1016/j.ijgo.2005.01.014.
9
Cervical cancer prevention in low-resource settings.资源匮乏地区的宫颈癌预防
Int J Gynaecol Obstet. 2005 Jul;90(1):86-7. doi: 10.1016/j.ijgo.2005.04.001.
引用本文的文献
1
A Clinical Decision Support System for Assessing the Risk of Cervical Cancer: Development and Evaluation Study.一种用于评估宫颈癌风险的临床决策支持系统：开发与评估研究
JMIR Med Inform. 2022 Jun 22;10(6):e34753. doi: 10.2196/34753.
2
Risk Estimates Supporting the 2019 ASCCP Risk-Based Management Consensus Guidelines.支持 2019 ASCCP 基于风险的管理共识指南的风险估计。
J Low Genit Tract Dis. 2020 Apr;24(2):132-143. doi: 10.1097/LGT.0000000000000529.
3
Triage of Women Testing Positive With the careHPV Test on Self-Collected Vaginal Samples for Cervical Cancer Screening in a Low-Resource Setting.在资源匮乏地区，对自我采集的阴道样本进行careHPV检测呈阳性的女性进行宫颈癌筛查的分诊
J Glob Oncol. 2018 Sep;4:1-7. doi: 10.1200/JGO.2016.008078. Epub 2017 Sep 29.
4
Mixture models for undiagnosed prevalent disease and interval-censored incident disease: applications to a cohort assembled from electronic health records.未诊断的流行疾病和区间删失发病疾病的混合模型：应用于从电子健康记录中汇集的队列研究
Stat Med. 2017 Sep 30;36(22):3583-3595. doi: 10.1002/sim.7380. Epub 2017 Jun 28.
5
Development and Validation of Risk Models to Select Ever-Smokers for CT Lung Cancer Screening.用于选择曾经吸烟者进行CT肺癌筛查的风险模型的开发与验证
JAMA. 2016 Jun 7;315(21):2300-11. doi: 10.1001/jama.2016.6255.
6
Automated recommendation for cervical cancer screening and surveillance.宫颈癌筛查与监测的自动化推荐
Cancer Inform. 2014 Oct 15;13(Suppl 3):1-6. doi: 10.4137/CIN.S14035. eCollection 2014.
7
Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines.以 CIN3+ 风险为基准，将 HPV 和巴氏涂片联合检测纳入宫颈癌筛查和管理指南。
J Low Genit Tract Dis. 2013 Apr;17(5 Suppl 1):S28-35. doi: 10.1097/LGT.0b013e318285423c.
8
Perceived risk of cervical cancer in Appalachian women.阿巴拉契亚女性对宫颈癌的感知风险。
Am J Health Behav. 2012 Nov;36(6):849-59. doi: 10.5993/AJHB.36.6.11.
9
Clinical utility in evaluation of risk models.风险模型评估中的临床效用。
Am J Epidemiol. 2012 Sep 15;176(6):495-6. doi: 10.1093/aje/kws255. Epub 2012 Aug 8.
10
Rationale and design of a multicenter prospective cohort study for the eVALuation and monitoring of HPV infections and relATEd cervical diseases in high-risk women (VALHIDATE study).多中心前瞻性队列研究的原理和设计，用于评估和监测高危女性的 HPV 感染和相关宫颈疾病（VALHIDATE 研究）。
BMC Cancer. 2012 May 30;12:204. doi: 10.1186/1471-2407-12-204.
本文引用的文献
1
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.人乳头瘤病毒（HPV）16/18 AS04佐剂疫苗预防致癌性HPV型别所致宫颈感染和癌前病变的疗效（PATRICIA）：一项针对年轻女性的双盲随机研究的最终分析
Lancet. 2009 Jul 25;374(9686):301-14. doi: 10.1016/S0140-6736(09)61248-4. Epub 2009 Jul 6.
2
HPV screening for cervical cancer in rural India.印度农村地区宫颈癌的人乳头瘤病毒筛查
N Engl J Med. 2009 Apr 2;360(14):1385-94. doi: 10.1056/NEJMoa0808516.
3
New technologies in cervical cancer screening.宫颈癌筛查中的新技术。
Vaccine. 2008 Aug 19;26 Suppl 10:K42-52. doi: 10.1016/j.vaccine.2008.05.002.
4
Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia.人乳头瘤病毒mRNA和p16检测作为改善宫颈肿瘤诊断的生物标志物。
Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2536-45. doi: 10.1158/1055-9965.EPI-08-0306.
5
A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China.一种用于发展中地区宫颈癌筛查的新型人乳头瘤病毒脱氧核糖核酸检测：中国农村地区临床准确性的横断面研究
Lancet Oncol. 2008 Oct;9(10):929-36. doi: 10.1016/S1470-2045(08)70210-9. Epub 2008 Sep 19.
6
Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial.人乳头瘤病毒DNA检测用于检测宫颈上皮内瘤变3级和癌症：一项随机对照实施试验的5年随访
Lancet. 2007 Nov 24;370(9601):1764-72. doi: 10.1016/S0140-6736(07)61450-0. Epub 2007 Oct 4.
7
Risk assessment to guide the prevention of cervical cancer.指导宫颈癌预防的风险评估
Am J Obstet Gynecol. 2007 Oct;197(4):356.e1-6. doi: 10.1016/j.ajog.2007.07.049.
8
2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests.2006年宫颈癌筛查异常女性管理共识指南
Am J Obstet Gynecol. 2007 Oct;197(4):346-55. doi: 10.1016/j.ajog.2007.07.047.
9
2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ.2006年宫颈上皮内瘤变或原位腺癌女性管理共识指南
Am J Obstet Gynecol. 2007 Oct;197(4):340-5. doi: 10.1016/j.ajog.2007.07.050.
10
Human papillomavirus and cervical cancer.人乳头瘤病毒与宫颈癌
Lancet. 2007 Sep 8;370(9590):890-907. doi: 10.1016/S0140-6736(07)61416-0.
Zotero 插件